Products
Secukinumab was approved as an injectable in many countries in 2015 (Cosentyx / -SensoReady).
Structure and properties
Secukinumab is a human IgG1κ monoclonal antibody. It is produced by biotechnological methods. The molecular mass is approximately 151 kDa.
Effects
Secukinumab (ATC L04AC10) binds to the cytokine interleukin-17A (IL-17A) and inhibits interaction with its receptor. As a result, the drug exerts anti-inflammatory and immunomodulatory effects.
Indications
For the treatment of plaque psoriasis.
Dosage
According to the SmPC. The drug is administered subcutaneously.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
Secukinumab should not be combined with live vaccines. Drug-drug interactions with CYP450 substrates cannot be excluded.
Adverse effects
The most common potential adverse effects include upper respiratory tract infections and diarrhea. Secukinumab is immunosuppressive and increases the risk for infectious diseases.
